Home › Compare › TTAZF vs ABBV
TTAZF yields 1.33% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, TTAZF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TTAZF + ABBV for your $10,000?
Tata Consumer Products Limited, together with its subsidiaries, produces and sells tea, coffee, and mineral water in India, Canada, the United States, the United Kingdom, Europe, the Middle East, South Africa, Australia, and internationally. The company operates through Branded Business and Non Branded Business segments. It engages in the processing and blending of tea, including the manufacture of instant tea. The company's products include food ingredients and sweeteners, salt, pulses, spices, ready-to-drink and ready-to-eat products, poha, flour, snacks, besan, cereals, ready-to-cook products, glucose-based ready-to-serve drinks, dry fruits, natural mineral water, packaged drinking water, functional beverages, and other packaged foods. It operates cafes under the Tata Cha brand. Tata Consumer Products Limited offers its products primarily under the Tata Tea, Tata Coffee Grand, Tata Water Plus, Tata Gluco Plus, Tata Fruski, Tetley, Tata Tea 1868, Teapigs, Vitax, Laager, Good Earth, Eight O'Clock Coffee, Himalayan, Tata Coffee Grand, and Joekels brands, as well as Tata Salt, Tata Soulfull, Tata Sampann, Sonnets by Tata Coffee, Tata Starbucks, Good Earth Kombucha, and Tata Q brands. The company was formerly known as Tata Global Beverages Limited and changed its name to Tata Consumer Products Limited in February 2020. Tata Consumer Products Limited was incorporated in 1962 and is headquartered in Mumbai, India.
Full TTAZF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.